- Meeting abstract
- Open Access
Using fraxiparin in patients with gestosis
Critical Care volume 4, Article number: P34 (2000)
The problem of treating the coagulate disorders in cases of gestosis remains of topical interest in obstetrics; heparin is dangerous because of the possible development of thrombocytopenia, heparin-induced thrombosis, osteoporosis, and increased consumption of anti-thrombin III.
The investigation was carried out in 2 groups of pregnant women with gestosis. To the first group (consisting of 34 patients aged 18–32), the injections of fraxiparin (2850 ME) were given once a day. To the second group (consisting of 32 patients aged 19–30), the injections of heparin (5000) were given 4 times a day. The effectiveness of the drug was checked clinically and according to the investigations of coagulate and thrombocyte gemostasis the day before the operation and on the 1st, 4th and 7th days after the operation.
In the group of patients with gestosis who received heparin, reduction of the number of thrombocytes to 21.4% (P<0.01) and growth of their aggregation activity to 18.3% (P<0.05) were observed on the 7th day of the postoperative period in comparison with the period prior to operation. In the group of pregnant women who received fraxiparin, a change in the number of thrombocytes and an increase in their aggregation activity were not observed.
The use of fraxiparin is more effective than treating with heparin and, as a result, it can be used for prophylaxis and treatment of thrombosis in pregnant women.
About this article
Cite this article
Elioutine, D., Marshalov, D. Using fraxiparin in patients with gestosis. Crit Care 4, P34 (2000). https://doi.org/10.1186/cc754
- Public Health
- Pregnant Woman